SCHEMBL23148488

SCHEMBL23148488

CCn1c2ccccc2c2cc(C(=S)c3ccc(C)c4ccccc34)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.55
▸ KDM4E B2RXH2 7/20 0.55
▸ LMNA P02545 5/20 0.55
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ HPGD P15428 3/20 0.49
▸ HTT P42858 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ HBB P68871 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ CNR2 P34972 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ TP53 P04637 2/20 0.45
▸ RORC P51449 2/20 0.44
▸ NPY5R Q15761 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600283 0.86 CNR2 (0.56) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL23148485 0.77 CNR2 (0.67) LMNAHPGDALDH1A1MAPK1CNR2
SCHEMBL23148497 0.76 MAPT (0.48) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL29370263 0.75 KDM4E (0.57) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL3417160 0.75 KDM4E (0.57) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL30832750 0.75 KDM4E (0.57) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL10579016 0.75 KDM4E (0.67) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL30659952 0.74 LMNA (0.66) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL21651447 0.74 LMNA (0.52) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL18889180 0.74 KDM4E (0.69) MAPTKDM4ELMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 — — US disclosed
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 — — US disclosed
US-11420967-B2 Modified carbazoles as therapeutic agents UNIVERSITY OF WASHINGTON (US) 2022-08-23 — — US disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 — — US disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C MAPT 23/4885KDM4E 3152/4885LMNA 1313/4885
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C MAPT 23/4885KDM4E 3152/4885LMNA 1313/4885
US-11420967-B2 Modified carbazoles as therapeutic agents TUBB3, TUBB1, TUBA1C MAPT 23/4885KDM4E 3152/4885LMNA 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback